



Editor's choice  
Scan to access more  
free content

# MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases

Cedric Chuan Young Ng,<sup>1,2</sup> Jing Tan,<sup>1,2</sup> Choon Kiat Ong,<sup>1,2</sup> Weng Khong Lim,<sup>1,2</sup> Vikneswari Rajasegaran,<sup>1,2</sup> Nur Diyana Md Nasir,<sup>3</sup> Jeffrey Chun Tatt Lim,<sup>3</sup> Aye Aye Thihe,<sup>3</sup> Syed Ahmed Salahuddin,<sup>3</sup> Javed Iqbal,<sup>3</sup> Inny Busmanis,<sup>3</sup> Angela Phek Yoon Chong,<sup>3</sup> Bin Tean Teh,<sup>1,2</sup> Puay Hoon Tan<sup>3</sup>

<sup>1</sup>Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore

<sup>2</sup>Division of Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore

<sup>3</sup>Department of Pathology, Singapore General Hospital, Singapore

## Correspondence to

Dr Puay Hoon Tan, Department of Pathology, Singapore General Hospital, Academia, Diagnostics Tower Level 7, 20 College Road, Singapore 169856, Singapore; tan.puay.hoon@sgh.com.sg

Received 24 January 2015

Revised 17 March 2015

Accepted 7 May 2015

Published Online First

27 May 2015

## ABSTRACT

**Aim** To determine the frequency of *MED12* mutations in a series of 112 breast phyllodes tumours, and to correlate the findings with clinicopathological parameters and survival outcomes.

**Methods** Phyllodes tumours from the Department of Pathology, Singapore General Hospital, were classified into benign, borderline and malignant categories.

Genomic DNA from formalin-fixed paraffin-embedded phyllodes tumours was extracted, purified and subjected to ultra-deep-targeted amplicon sequencing across exon 2 of the *MED12* gene. Sequencing was performed on the Illumina MiSeq next-generation sequencing platform and bioinformatics analysis applied. Appropriate statistical analyses were carried out.

**Results** There were 66 benign, 32 borderline and 14 malignant tumours, with 43 (65.1%), 21 (65.6%) and 6 (42.8%) disclosing *MED12* mutations (missense, splice site, indel), respectively. For 97 cases with available follow-up, there were 10 (10.3%) recurrences. Patients with phyllodes tumours that harboured *MED12* mutations experienced improved disease-free survivals, with higher recurrence likelihood in those without *MED12* mutations (HR 9.99, 95% CIs 1.55 to 64.42,  $p=0.015$ ).

**Conclusions** Similar to fibroadenomas, phyllodes tumours show a high frequency of *MED12* mutations, affirming the close biological relationship between these fibroepithelial neoplasms.

## INTRODUCTION

Phyllodes tumours of the breast are unusual and infrequently encountered fibroepithelial neoplasms which bear clinicopathological resemblance to the common fibroadenoma.<sup>1</sup> The relationship between phyllodes tumours and fibroadenomas has been a subject of long-standing discussion. Apart from microscopic similarities of the phyllodes tumour to the intracanalicular fibroadenoma, the finding of fibroadenoma juxtaposed to phyllodes tumour is a familiar experience of pathologists during routine diagnostic work. While the fibroadenoma is a benign and clinically innocuous lesion, the phyllodes tumour is regarded as a neoplasm that has a tendency to recur, with recurrence rates increasing from benign to borderline and malignant tumours.<sup>2</sup>

Published data on the biological link between these tumours are scant. There is a report of three cases of fibroadenomas progressing to phyllodes tumours, whereby patients with initial diagnoses of fibroadenoma later recurred as phyllodes tumours.<sup>3</sup> In that report, clonality studies found the original

fibroadenomas to be monoclonal, but whether they could have been undersampled phyllodes tumours was not addressed. Another group described clonality analysis of fibroadenomas, discovering one 'simple' fibroadenoma and one complex fibroadenoma with monoclonality of stroma. The monoclonal 'simple' fibroadenoma was histologically described to contain a phyllodes component, which also demonstrated stromal monoclonality.<sup>4</sup> Kuijper *et al*<sup>5</sup> found monoclonality in areas of apparent stromal expansion within fibroadenomas and suggested that there could be stromal progression of fibroadenoma to phyllodes tumour. Another study<sup>6</sup> observed identical loss at the same microsatellite locus in a synchronous fibroadenoma and phyllodes tumour of the same breast, while allelic losses at TP53 and another microsatellite locus were detected in the phyllodes tumour but not in the synchronous fibroadenoma. The authors suggested that the latter could be implicated in progression of fibroadenoma to phyllodes tumour. In a study that included 36 malignant phyllodes tumours by a Japanese group,<sup>7</sup> 11 were associated with previous fibroadenomas, which could be interpreted as progression of fibroadenomas to phyllodes tumours. Interestingly, they concluded that there was a better clinical outcome in malignant phyllodes tumours preceded by fibroadenomas than in those diagnosed *de novo*.

Recently, we discovered highly recurrent *MED12* somatic mutations in 59% of fibroadenomas using exome sequencing.<sup>8</sup> *MED12* is a gene on the X chromosome that encodes the Mediator complex subunit 12, which is a multiprotein complex widely involved in transcriptional regulation of gene expression.<sup>9</sup> Since our initial publication, there have been additional reports of *MED12* mutations in fibroadenomas as well as phyllodes tumours,<sup>10–14</sup> with some demonstrating a lower frequency of *MED12* mutations in malignant than benign and borderline phyllodes tumours.<sup>11–13</sup> In light of the intertwining link between fibroadenomas and phyllodes tumours, we therefore embarked on determining the frequency and spectrum of *MED12* aberrations in a large series of breast phyllodes tumours, as well as to compare against those previously documented in fibroadenomas.

## MATERIALS AND METHODS

### Clinical specimens

Phyllodes tumours were diagnosed and subtyped according to histopathological examination of surgically excised tumours, using criteria recommended



CrossMark

**To cite:** Ng CCY, Tan J, Ong CK, *et al.* *J Clin Pathol* 2015;**68**:685–691.

by the WHO classification of breast tumours.<sup>1</sup> Briefly, a benign phyllodes tumour was diagnosed when a fibroepithelial neoplasm with exaggerated intracanalicular pattern and fronded architecture was accompanied by mild stromal cellularity with minimal to mild nuclear atypia, pushing borders and mitoses of four or less per 10 high power fields, without stromal overgrowth. The diagnosis of a malignant phyllodes tumour was rendered when there was marked stromal cellularity, marked atypia, stromal overgrowth, permeative margins and mitotic activity of 10 or more per 10 high power fields. Tumours with intermediate features were regarded as borderline.<sup>15</sup> A total of 112 phyllodes tumours were included in this study, derived from archival formalin-fixed paraffin-embedded (FFPE) samples of excision specimens processed and handled by the Department of Pathology, Singapore General Hospital.

### DNA extraction

Genomic DNA (gDNA) from FFPE tissue was extracted and purified using the Qiagen FFPE DNA kit according to the manufacturer's guidelines. gDNA yield and quality were determined using Picogreen fluorometric analysis as well as visual inspection of agarose gel electrophoresis images.

### Ultra-deep-targeted amplicon sequencing of *MED12* exon 2

For sensitive detection of low-frequency variants in *MED12* exon 2, we used ultra-deep-targeted amplicon sequencing. Six PCR amplicons were designed and tiled across exon 2 of *MED12*. We then used Fluidigm's Access Array System to generate and pool the amplicons according to the manufacturer's instructions. For each sample, 50 ng of gDNA was used as template. Sequencing library preparation of the pooled amplicons was performed using the TruSeq HT DNA Sample Preparation Kit (Illumina) according to the manufacturer's instructions. Sequencing was performed on the Illumina MiSeq next-generation sequencing platform for 150 cycles using the MiSeq Reagent kit V3.


Bioinformatics analysis of sequencing reads was performed. Briefly, undetermined ('N') base calls at the ends of reads were trimmed. Following this, the 5' end of each read was trimmed by 25 bases to eliminate the possibility of primer inclusion. The Burrows–Wheeler Alignment<sup>16</sup> tool (0.6.2) was used to align the resulting reads to the reference human genome (hg19). For more sensitive detection of insertions and deletions (indels), we also ran a separate alignment process using modified settings ( $o=2$ ,  $e=30$ ,  $d=30$ ,  $O=0$ ,  $E=0$ ,  $L=0$ ). Indels were identified through manual inspection, whereas automated detection of point mutations was performed using the samtools<sup>17</sup> (0.1.18) *mpileup* tool. Variant calls were restricted to regions covered by amplicons. Variant allele frequencies were calculated for each position in the targeted region, and those that exceeded a threshold of 5% were considered candidate variants. In order to minimise the possibility of PCR-induced artifacts, variants were only considered valid if present in at least two amplicons. Candidate variants had at least 21 620 sequencing reads overlapping them, with an average coverage of 184 526 reads.

To ascertain the sensitivity of our assay, positive control samples containing spiked-in validated mutant *MED12* at allele frequencies (15%, 10%, 5% and 3%) were generated via serial dilutions. We accurately detected variants in positive control samples at allele frequencies down to 3%. We also calculated alternate (non-reference) allele frequencies across all positions in our target region in order to estimate the likelihood of error from sequencing and alignment artifacts. The mean alternate

allele frequency was 0.281% with a SD of 1.09%. Thus, our detection threshold of 5% exceeds four SDs from the estimated background error rate.

### Statistical analysis

Statistical analyses were performed in R. The relationship between clinicopathological parameters and *MED12* mutational status was tested using Fisher's exact tests as appropriate. Follow-up data were obtained from patient casenotes. Disease-free survival (DFS) was defined as time from diagnosis to recurrence or date of last follow-up. DFS was estimated with the Kaplan–Meier analysis and compared between groups using the log-rank statistics. Multivariate Cox regression was carried out to evaluate the effect of *MED12* mutations on DFS. HRs together with 95% CIs were reported. A p value of <0.05 defined statistical significance.



**Figure 1** (A) Benign phyllodes tumour shows prominent leafy stromal fronds covered by benign epithelium, accompanied by patchy mild stromal hypercellularity, with pushing rounded borders. (B) Borderline phyllodes tumour demonstrates a greater degree of stromal hypercellularity and less well-defined borders. (C) Malignant phyllodes tumour discloses stromal overgrowth with marked stromal nuclear pleomorphism and brisk mitoses.

**Table 1** Association between clinicopathological features of phyllodes tumours and *MED12* mutations (N=112)

Clinicopathological features	Total	<i>MED12</i> mutations	Without <i>MED12</i> mutations	p Value
Age (years; median 43, IQR 32–52 years)				0.332
<Mean age	52	35 (67.3%)	17 (32.7%)	
≥Mean age	60	35 (58.3%)	25 (41.7%)	
Ethnicity				0.372
Chinese	75	46 (61.3%)	29 (38.7%)	
Malay	9	4 (44.4%)	5 (55.6%)	
Indian	3	2 (66.7%)	1 (33.3%)	
Others	25	18 (72.0%)	7 (28.0%)	
Grade				0.217
Benign	66	43 (65.1%)	23 (34.9%)	
Borderline	32	21 (65.6%)	11 (34.4%)	
Malignant	14	6 (42.8%)	8 (57.2%)	
Size (mm; median 40, IQR 27–60 mm)				0.322
<Mean size	68	45 (43.8%)	23 (56.2%)	
≥Mean size	44	25 (56.8%)	19 (43.2%)	
Microscopic borders				0.553
Circumscribed	81	52 (64.2%)	29 (35.8%)	
Permeative	31	18 (58.1%)	13 (41.9%)	
Stromal hypercellularity				0.570
Mild	41	26 (63.4%)	15 (36.6%)	
Moderate	59	38 (64.4%)	21 (35.6%)	
Marked	12	6 (50.0%)	6 (50.0%)	
Stromal atypia				0.234
Mild	78	53 (67.9%)	25 (32.1%)	
Moderate	25	11 (44.0%)	14 (56.0%)	
Marked	9	6 (66.7%)	3 (33.3%)	
Stromal overgrowth				0.191
Absent	92	58 (63.0%)	34 (37.0%)	
Present	20	12 (60.0%)	8 (40.0%)	
Mitotic activity/10 HPFs				0.775
0–4	64	40 (62.5%)	24 (37.5%)	
5–9	29	17 (58.6%)	12 (41.4%)	
≥10	19	13 (68.4%)	6 (31.6%)	

HPF, high power field.

## RESULTS

Phyllodes tumours were histologically subdivided into benign, borderline and malignant grades according to the WHO criteria (figure 1),<sup>1</sup> with 66 benign, 32 borderline and 14 malignant tumours. Detailed clinicopathological features are shown in table 1. All 112 phyllodes tumours were subjected to amplicon sequencing analysis for the presence of *MED12* exon 2 mutations (table 2). Overall, 70 (62.5%) of phyllodes tumours demonstrated *MED12* mutations. Figures 2 and 3 show the distribution of somatic mutations among phyllodes tumours in this series, compared with those reported for our previous study on fibroadenomas.

Follow-up information was available for 97 cases, with mean and median durations of 32 and 30 months, respectively (IQR, 1.24–3.70 years). There were 10 (10.3%) recurrences, constituted by three (5.3%) of 57 benign, five (17.2%) of 29 borderline and two (18.2%) of 11 malignant tumours. Patients with phyllodes tumours that harboured *MED12* mutations experienced improved DFS than those without mutations (figure 4). On univariate analysis, the only parameter that correlated with recurrence was *MED12* status (table 3). Multivariate Cox regression analysis, with adjustment for age, grade, tumour size and ethnicity showed a HR of 9.99 (95% CIs 1.55 to 64.42,  $p=0.015$ ) for tumours without *MED12* mutations.

## DISCUSSION

The *MED12* gene is located on the long arm of the X chromosome. The protein that it encodes, mediator complex subunit 12, forms a part of the mediator complex that comprises 25 proteins working together in concert to regulate gene activity.<sup>18</sup> The *MED12* protein is involved in early neuronal development as well as cellular signalling that governs cell growth, migration and differentiation. Germline mutations in the *MED12* gene are linked to several syndromes,<sup>19 20</sup> while somatic mutations are described in a variety of tumours including uterine smooth muscle tumours, prostatic and colonic adenocarcinomas<sup>18 21–23</sup> and more recently, fibroadenomas and phyllodes tumours of the breast.<sup>8 10</sup>

In this series of breast phyllodes tumours, the overall rate of *MED12* mutations of 62.5% is similar to the 59% frequency in fibroadenomas,<sup>8</sup> affirming the close molecular relationship between these neoplasms. In addition, the majority of *MED12* mutations (52 of 70; 74%) involved codon 44, comparable again with the 71% *MED12* codon 44 aberrations documented in our previously described fibroadenomas.<sup>8</sup> When phyllodes tumours were separated into benign, borderline and malignant varieties, 65.1%, 65.6% and 42.8% showed *MED12* mutations, respectively.

**Table 2** High frequency of *MED12* exon 2 mutations in phyllodes tumours of breast


Type	cDNA (CCDS43970.1)	Protein	Number of mutations	Frequency (%)	
Missense	c.131G>C	p.G44A	3	2.7	
	c.131G>A	p.G44D	18	16.1	
	c.131G>T	p.G44V	13	11.6	
	c.130G>A	p.G44S	8	7.1	
	c.130G>C	p.G44R	5	4.5	
	c.130G>T	p.G44C	5	4.5	
	c.107T>G	p.L36P	1	0.9	
	Splice site	Exon2 (-8 T>A)	p.E33_D34insPQ	4	3.6
Indel	c.128_130delAAG	p.43_44QG>R	1	0.9	
	c.107_115delTGACGGCCT	p.36_39LTAL>L	1	0.9	
	c.118_138delAATGTAACAAGGTTTCAAT	p.NVKGFN40del	1	0.9	
	c.123_131delAAAAACAAGG	p.KQG42del	1	0.9	
	c.134_151delTCAATAACCAGCCTGCTG	p.NNQPAV46del	1	0.9	
	c.133_150delITTCATAACCAGCCTGC	p.FNNQPA45del	1	0.9	
	c.129_131delAGG	p.43_44QG>H	1	0.9	
	c.124_144delAAACAAGGTTTCAATAACCAG	p.KQGFNNQ42del	1	0.9	
	c.100_120delGATGAAGTACGGCCTTGAAT	p.DELTALN34del	1	0.9	
	c.105_131delACTGACGGCCTTGAATGTAACAACAAGG	p.35_44ELTALNVKQG>D	1	0.9	
	c.133_144delITTCATAACCAG	p.FNNQ45del	1	0.9	
	c.143_163delAGCCTGCTGTCTGGGGATG	p.PAVSGDE49del	1	0.9	
	c.132_149delITTCATAACCAGCCTGC	p.FNNQPA45del	1	0.9	
	Total			70	62.5

The histological distinction of fibroadenoma, particularly the cellular variety, from phyllodes tumour is a constant challenge, even among pathologists who specialise in breast pathology.<sup>24</sup> Occurrence of *MED12* mutations in phyllodes tumours in a similar frequency to that in fibroadenomas provides the biological basis to this likeness, despite the divergence in recurrence rates and clinical progression.


Apart from breast fibroepithelial neoplasms, *MED12* mutations have been detected in uterine leiomyomas.<sup>18 23</sup> The uterine leiomyoma is a benign tumour which occurs in an organ

that is hormonally responsive, similar to the breast. While *MED12* aberrations are common in the leiomyoma, they are rare in its malignant counterpart—the leiomyosarcoma.<sup>22</sup> If the role of *MED12* in both fibroadenomas and leiomyomas is related to oestrogen regulation as postulated,<sup>8</sup> the lower rate of mutations in malignant phyllodes tumours may implicate a loss of dependence on the oestrogen regulation pathway in the development of this subset, a consideration that can be partially and indirectly supported by a study that found decreasing epithelial hormonal expression with increasing malignancy in

**Figure 2** Comparison of *MED12* exon 2 mutations in fibroadenomas (FA) and phyllodes tumours (PT) shows a similar distribution in both tumours.



**Figure 3** Frequency of *MED12* somatic variants in fibroadenomas (FA) and phyllodes tumours (benign, borderline, malignant). Splice site mutations are observed only in FA and benign phyllodes tumours.



phyllodes tumours.<sup>25</sup> It is likely that other genetic aberrations contribute to the development of malignant phyllodes tumours or are harnessed in the progression of benign phyllodes tumours to the malignant variety.


Cani *et al*<sup>10</sup> described frequent *MED12* mutations (67%) across all three histological grades of 15 breast phyllodes tumours, with individual subset mutational rates of 80%, 80% and 40% in benign, borderline and malignant tumours, respectively. Loss of function mutations in p53 and deleterious mutations in Rb1 and NF1 were exclusively detected only in the malignant grade.<sup>10</sup> These additional mutational events in

tumour suppressor genes are likely responsible for acquisition of malignant characteristics and aggressive biological behaviour in phyllodes tumours.

There were no statistically significant correlations between clinicopathological characteristics of our series of phyllodes tumours and *MED12* mutations, suggesting that *MED12* may not be specifically linked to, or be responsible for, histological alterations used in the grading of these tumours. Nevertheless, the presence of *MED12* mutations augured a better prognosis for women with phyllodes tumours, with those cases lacking *MED12* aberrations demonstrating close to tenfold increased likelihood of recurrence. The underlying reason for this improved clinical behaviour of phyllodes tumours harbouring *MED12* mutations is uncertain and may be related to the suggestion of hormonal dependence of neoplasms bearing *MED12* aberrations.

Limitations of this study include the relatively few number of malignant phyllodes tumours which may affect the dependability of the reported *MED12* mutation rates in the subset. While no laser capture microdissection was performed in this study of paraffinised tumour samples to verify that *MED12* mutations were indeed confined to the stromal component, our previous work on fibroadenomas<sup>8</sup> as well as phyllodes tumours unpublished (unpublished) had verified the stromal origin of *MED12* mutations through laser microdissected material. In addition, the few recurrences resulted in relatively wide CIs, reducing statistical robustness.

In summary, our study of 112 phyllodes tumours shows a similar rate of *MED12* mutations as previously reported in breast fibroadenomas, underscoring their close biological relationship. Malignant phyllodes tumours were less frequently associated with *MED12* mutations (42.8%) although this was not a statistically significant finding. No correlations were found with other clinicopathological features. Tumours with *MED12* mutations demonstrated an improved DFS which may provide insights into its biological role. More work to elucidate accompanying genomic abnormalities that drive aggressive behaviour in borderline and malignant phyllodes tumours is needed to expand the current understanding of this group of fascinating neoplasms.



**Figure 4** Kaplan–Meier survival analysis showed an improved disease-free survival for patients whose tumours disclosed *MED12* mutations.

**Table 3** Univariate analysis of clinicopathological parameters with disease-free survival

Factor	Number of events	HR (95% CI)	p Value
<b>Age</b>			
<Mean age	5/43	Reference	
≥Mean age	5/54	3.92 (0.50 to 30.7)	0.193
<b>Size</b>			
<Mean size	3/57	Reference	
≥Mean size	7/37	0.736 (0.09 to 6.07)	0.776
<b>Ethnicity</b>			
Chinese	4/66	Reference	
Malay	1/8	0.12 (0.01 to 1.32)	0.083
Indian	0/3	0.85 (0.02 to 31.03)	0.928
Others	5/20	0.01 (0.01 to 2.49)	0.513
<b>Grade</b>			
Benign	3/57	Reference	
Borderline	5/29	0.84 (0.01 to 63.89)	0.935
Malignant	2/11	0.46 (0.02 to 11.77)	0.639
<b>Stromal hypercellularity</b>			
Mild	1/37	Reference	
Moderate	8/51	0.37 (0.01 to 245.55)	0.762
Marked	1/9	3.64 (0.02 to 589.29)	0.619
<b>Stromal atypia</b>			
Mild	6/68	Reference	
Moderate	3/22	1.66 (0.004 to 749.20)	0.871
Marked	1/7	1.18 (0.01 to 210.94)	0.951
<b>Mitotic activity (per 10 HPFs)</b>			
0–3	3/57	Reference	
4–9	4/23	0.34 (0.03 to 4.36)	0.405
≥10	3/17	1.07 (0.112 to 10.16)	0.954
<b>Stromal overgrowth</b>			
Absent	7/83	Reference	
Present	3/14	8.19 (0.00 to 7.22)	0.953
<b>Microscopic borders</b>			
Circumscribed		Reference	
Permeative		1.45 (0.13 to 15.92)	0.759
<b>MED12 mutations</b>			
Present	3/60	Reference	
Absent	7/37	24.76 (2.45 to 247.7)	0.006

### Take home messages

- ▶ The *MED12* gene, found on the X chromosome, encodes the Mediator complex subunit 12, a multiprotein complex widely involved in transcriptional regulation of gene expression.
- ▶ *MED12* is frequently mutated in breast fibroadenomas (59%) and phyllodes tumours (62.5%), underscoring their close biological relationship, and suggests a role in initiation of these neoplasms.
- ▶ *MED12* mutations have a slightly lower frequency in malignant phyllodes tumours (42.8%), though this finding is not statistically significant.
- ▶ The improved disease-free survival of patients whose phyllodes tumours harboured *MED12* mutations may reflect its effect on biological behaviour.

**Handling editor** Cheok Soon Lee

**Contributors** CCYN, JT, CKO, WKL, VR performed the experiments and analysed the bioinformatics data. NDMN and JCTL carried out the histotechnical aspects.

AAT, SAS, JI, IB and APYC reviewed the cases. BTT and PHT initiated and supervised the study, reviewed and wrote the manuscript.

**Funding** This work was supported in part by funding from the Singapore National Medical Research Council (NMRC/STAR/0006/2009) and the Singapore National Cancer Centre Research Fund.

**Competing interests** None declared.

**Ethics approval** SingHealth Centralised Institutional Review Board (2005/002/F).

**Provenance and peer review** Not commissioned; externally peer reviewed.

### REFERENCES

- 1 Tan PH, Tse G, Lee A, *et al.* Fibroepithelial tumours. In: Lakhani S, Ellis I, Schnitt S, *et al.*, eds. *Who classification of tumours of the breast*. Lyon: International Agency for Research on Cancer, 2012:142–7.
- 2 Tan PH, Thike AA, Tan WJ, *et al.* Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. *J Clin Pathol* 2012;65:69–76.
- 3 Noguchi S, Yokouchi H, Aihara T, *et al.* Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. *Cancer* 1995;76:1779–85.
- 4 Kasami M, Vnencak-Jones CL, Manning S, *et al.* Monoclonality in fibroadenomas with complex histology and phyllod features. *Breast Cancer Res Treat* 1998;50:185–91.
- 5 Kuijper A, Buerger H, Simon R, *et al.* Analysis of the progression of fibroepithelial tumours of the breast by pcr-based clonality assay. *J Pathol* 2002;197:575–81.

- 6 Hodges KB, Abdul-Karim FW, Wang M, *et al.* Evidence for transformation of fibroadenoma of the breast to malignant phyllodes tumor. *Appl Immunohistochem Mol Morphol* 2009;17:345–50.
- 7 Abe M, Miyata S, Nishimura S, *et al.* Malignant transformation of breast fibroadenoma to malignant phyllodes tumor: Long-term outcome of 36 malignant phyllodes tumors. *Breast Cancer* 2011;18:268–72.
- 8 Lim WK, Ong CK, Tan J, *et al.* Exome sequencing identifies highly recurrent *MED12* somatic mutations in breast fibroadenoma. *Nat Genet* 2014;46:877–80.
- 9 Wang H, Shen Q, Ye LH, *et al.* *MED12* mutations in human diseases. *Protein Cell* 2013;4:643–6.
- 10 Cani AK, Hovelson DH, McDaniel AS, *et al.* Next-gen sequencing exposes frequent *MED12* mutations and actionable therapeutic targets in phyllodes tumors. *Mol Cancer Res* 2015;13:613–19.
- 11 Nagasawa S, Maeda I, Fukuda T, *et al.* *MED12* exon 2 mutations in phyllodes tumors of the breast. *Cancer Med* 2015 Apr 13. [Epub ahead of print]
- 12 Pfarr N, Kriegsmann M, Sinn P, Klauschen F, *et al.* Distribution of *MED12* mutations in fibroadenomas and phyllodes tumors of the breast-implications for tumor biology and pathological diagnosis. *Genes Chromosomes Cancer* 2015 Apr 30. [Epub ahead of print]
- 13 Piscuoglio S, Murray M, Fusco N, *et al.* *MED12* somatic mutations in fibroadenomas and phyllodes tumors of the breast. *Histopathology* 2015 Apr 8. [Epub ahead of print]
- 14 Yoshida M, Sekine S, Ogawa R, *et al.* Frequent *MED12* mutations in phyllodes tumours of the breast. *Br J Cancer* 2015;112:1703–8.
- 15 Tan PH, Jayabaskar T, Chuah KL, *et al.* Phyllodes tumors of the breast: The role of pathologic parameters. *Am J Clin Pathol* 2005;123:529–40.
- 16 Li H, Durbin R. Fast and accurate short read alignment with burrows-wheeler transform. *Bioinformatics* 2009;25:1754–60.
- 17 Li H, Handsaker B, Wysoker A, *et al.* The sequence alignment/map format and samtools. *Bioinformatics* 2009;25:2078–9.
- 18 Barbieri CE, Baca SC, Lawrence MS, *et al.* Exome sequencing identifies recurrent *spop*, *foxa1* and *med12* mutations in prostate cancer. *Nat Genet* 2012;44:685–9.
- 19 Ding N, Zhou H, Esteve PO, *et al.* Mediator links epigenetic silencing of neuronal gene expression with x-linked mental retardation. *Mol Cell* 2008;31:347–59.
- 20 Risheg H, Graham JM Jr, Clark RD, *et al.* A recurrent mutation in *med12* leading to *r961w* causes opitz-kaveggia syndrome. *Nat Genet* 2007;39:451–3.
- 21 Makinen N, Mehine M, Tolvanen J, *et al.* *Med12*, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. *Science* 2011;334:252–5.
- 22 Kampjarvi K, Makinen N, Kilpivaara O, *et al.* Somatic *med12* mutations in uterine leiomyosarcoma and colorectal cancer. *Br J Cancer* 2012;107:1761–5.
- 23 Je EM, Kim MR, Min KO, *et al.* Mutational analysis of *med12* exon 2 in uterine leiomyoma and other common tumors. *Int J Cancer* 2012;131:E1044–7.
- 24 Lawton TJ, Acs G, Argani P, *et al.* Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors. *Int J Surg Pathol* 2014;22:695–8.
- 25 Tse GMK, Lee CS, Kung FYL, *et al.* Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: A multicenter study of 143 cases. *Am J Clin Pathol* 2002;118:522–6.